minocycline HCl

minocycline HCl

(min´ōsī´klēn),
n brand names: Dyancin, Minocin;
drug class: tetracycline antiinfective;
action: inhibits protein synthesis, phosphorylation in microorganisms by binding 30S ribosomal subunits, reversibly binding to 50S ribosomal subunits; bacteriostatic;
uses: syphilis,
Chlamydia trachomatis infection, gonorrhea, lymphogranuloma venereum, rickettsial infections, inflammatory acne. Also used in the treatment of some periodontal infections, generally in conjunction with mechanical therapy.
Mentioned in ?
References in periodicals archive ?
For the 12 months ending December 2017, Minocycline HCl extended-release tablets, 65 mg and 115 mg, had annual US sales of about USD148m according to IQVIA,
At concentrations comparable to therapeutic blood levels, minocycline HCL inhibited ROS ([O.
More specifically, the 97 study participants aged 12-29 years, all with grade 3-4 moderate to severe facial acne by Investigator's Global Assessment (IGA), were placed on once-daily minocycline HCL extended release at about 1 mg/kg, clindamycin phosphate 1.
Pigmentation of the jawbones and teeth secondary to minocycline HCl therapy.